KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $7.6 billion.

  • BeOne Medicines' Liabilities and Shareholders Equity rose 3089.98% to $7.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $25.7 billion, marking a year-over-year increase of 1163.29%. This contributed to the annual value of $5.9 billion for FY2024, which is 199.19% up from last year.
  • As of Q3 2025, BeOne Medicines' Liabilities and Shareholders Equity stood at $7.6 billion, which was up 3089.98% from $6.3 billion recorded in Q2 2025.
  • BeOne Medicines' 5-year Liabilities and Shareholders Equity high stood at $8.5 billion for Q4 2021, and its period low was $5.3 billion during Q3 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $5.8 billion (2024), whereas its average is $6.2 billion.
  • In the last 5 years, BeOne Medicines' Liabilities and Shareholders Equity skyrocketed by 5239.95% in 2021 and then crashed by 3578.39% in 2022.
  • BeOne Medicines' Liabilities and Shareholders Equity (Quarter) stood at $8.5 billion in 2021, then crashed by 35.78% to $5.5 billion in 2022, then grew by 5.91% to $5.8 billion in 2023, then increased by 1.99% to $5.9 billion in 2024, then grew by 28.91% to $7.6 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $7.6 billion for Q3 2025, versus $6.3 billion for Q2 2025 and $5.8 billion for Q1 2025.